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A 62-year-old man developed a right quadriceps mass in May 2011; biopsy demonstrated a high-grade undif-
ferentiated pleomorphic sarcoma. A wide resection of a 
15 × 10 × 6.8 cm tumor was performed with negative mar-
gins. He received 6000 cGy adjuvant radiation. A computed 
tomography (CT) scan in May 1, 2012 demonstrated two 
new pulmonary nodules in the left to 10 mm, and one in 
the right. CT-guided biopsy of the largest left lung nod-
ule on May 17, 2012 confirmed metastasis. He received 
two cycles of doxorubicin and ifosfamide through June 
2012. A restaging CT scan on July 5, 2012 demonstrated 
progression in the two left-sided pulmonary nodules, up 
to 18 mm. He then received pazopanib 800 mg daily. CT 
scan 2 months later demonstrated marked regression in the 
left-sided pulmonary metastases from 18 to 8 mm (Fig. 1), 
along with regression of the largest right-sided pulmo-
nary lesion from 5 to 2 mm (Fig. 2). Therefore, the patient 
underwent metastasectomy via left-sided video-assisted 
thoracoscopic surgery. During surgery, five nodules were 
found and treated with wedge resections. Postsurgery CT 
showed only scattered unchanged micronodules in the 
right lung. Pathology demonstrated a complete pathologic 
response with no viable tumor in any of the resected nodules 
(Fig. 3A and B). Patient was continued on pazopanib for 
3 more months. Repeat CT imaging February 14, 2013 
showed only postsurgical changes in the left upper lobe with 
unchanged micronodules in the right.
DISCUSSION
Soft tissue sarcomas (STSs) are malignant, mesenchymal 
tumors that comprise more than 50 different histological 
subtypes. Surgery and radiation are the principal treat-
ments for localized tumors. Adjuvant chemotherapy has not 
improved survival, and outcomes for recurrent or metastatic 
STS are poor because of their relative insensitivity to che-
motherapy. Distant metastases will develop in about 25% of 
patients, with increased rates in 5 cm or higher-grade tumors; 
in more than 70% of patients, metastases will be to the lung.1 
Pulmonary metastatectomy for sarcoma is established as 
standard of care; one systemic review of 1357 pulmonary 
metastasectomy patients revealed 25% alive after 5 years 
after the surgery, with better survival in patients with fewer 
metastases and longer interval from diagnosis.2 However, to 
date there has been no randomized trial comparing survival 
in patients who undergo pulmonary metastasectomy versus 
no surgery.
Pazopanib is an oral angiogenesis inhibitor of multiple 
targets including vascular endothelial growth factor, platelet-
derived growth factor, and c-kit receptors. There were nine 
partial responses but no complete responses in a phase 2 trial 
of pazopanib in 138 advanced STS patients.3 A phase 3 trial 
compared pazopanib to placebo in advanced STS patients 
who had progressed after chemotherapy. Pazopanib provided 
a 3-month improvement in median progression-free survival 
from 1.6 to 4.6 months, leading to United States Food and 
Drug Administration approval in advanced nonliposarcoma 
STS after failure of anthracycline chemotherapy.4 There were 
14 partial responses among the 246 patients randomized to 
pazopanib, although it is unclear how many were undifferenti-
ated pleomorphic sarcoma. There were no complete responses. 
To the best of our knowledge, this is the first report of a patho-
logic complete response to pazopanib in advanced STS.
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FIGURE 1.  Restaging CT scan after doxorubicin and ifosfamide chemotherapy on July 5, 2012 (left) demonstrated progression 
in the two left-sided pulmonary nodules, up to 18 mm. Patient was treated with pazopanib. Follow-up CT scan on September 
27, 2012 (right) demonstrated a marked regression in the left-sided pulmonary metastases from 18 to 8 mm. CT, computed 
tomography.
FIGURE 2.  Response in the largest right-sided pulmonary lesion from 5 to 2 mm after 2 months of pazopanib. Arrows indicate 
the lung metastases responding to pazopanib.
FIGURE 3. A, Pulmonary metastasis biopsy (May 17, 2012): the high power (H&E, 40×) demonstrates a high-grade spindle 
cell sarcoma with highly pleomorphic cells, bizarre multinucleated giant cells, and numerous mitotic figures. B, Wedge resec-
tion of pulmonary metastases (October 22, 2012) that had regressed on CT imaging after pazopanib was initiated showed only 
fibrosis, mild inflammatory infiltrate of histiocytes, and a few lymphoid cells. No viable tumor was identified (H&E, 4×). CT, 
computed tomography; H&E, hematoxylin and eosin.
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